| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2679244 | Seminars in Oncology Nursing | 2014 | 8 Pages |
ObjectivesTo review common cardiac side effects, their clinical presentation, and recommendations for assessment and management of patients receiving molecularly targeted cancer therapies.Data sourcesPeer-reviewed literature.ConclusionAlthough there is no established guideline for pretreatment cardiac evaluation and monitoring of patients receiving molecularly targeted agents, data currently supports the need for early risk identification and prevention/reduction strategies.Implications for Nursing PracticeAs nurses, we have a unique opportunity to help improve and maintain the quality of life of cancer survivors. Cardiovascular assessment and prevention/reduction strategies are essential to reduce risk of cardiovascular disease, promote optimal quality of life, and improve survival outcomes in patients receiving molecularly targeted cancer treatment.
